DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Harbeck N, Gluz O, Clemens MR. et al.
Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC→4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer.
J Clin Oncol 2017;
35 (Suppl. 15) 504
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.